CD19 and neoplasm: Pioneering work by Christian J. Buchholz et al. demonstrated the induction of CAR-T cells in situ in immunodeficient mice using second-generation anti-CD19-CAR gene-encapsulated LV, exhibiting anti-tumor activity 106.